HARROW HEALTH, INC. Business Finance Contracts & Agreements

Underwriting Agreement between the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein, dated July 18, 2023 (Filed With SEC on July 21, 2023)

Loan and Security Agreement dated December 14, 2022, between the Company and B. Riley Commercial Capital, LLC (Filed With SEC on May 11, 2023)

Second Supplemental Indenture, dated as of December 20, 2022, by and between the Company and U.S. Bank Trust Company, National Association (Filed With SEC on December 20, 2022)

Common Stock Underwriting Agreement between the Company and B. Riley Securities, Inc. dated December 13, 2022 (Filed With SEC on December 16, 2022)

Notes Underwriting Agreement between the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein, dated December 15, 2022 (Filed With SEC on December 16, 2022)

Asset Purchase Agreement dated December 13, 2022, between the Company and Novartis Technology, LLC and Novartis Innovative Therapies AG (Filed With SEC on December 14, 2022)

First Amendment to Loan and Security Agreement, dated as of April 8, 2022, between the Company and Melt Pharmaceuticals, Inc (Filed With SEC on November 14, 2022)

Second Amendment to Loan and Security Agreement, dated as of September 21, 2022, between the Company and Melt Pharmaceuticals, Inc (Filed With SEC on November 14, 2022)

First Amendment to Loan and Security Agreement, dated as of April 8, 2022, between the Company and Melt Pharmaceuticals, Inc (Filed With SEC on August 9, 2022)

Asset Purchase Agreement, dated as of December 17, 2021, by and between the Company and Novartis Technology, LLC and Novartis Ophthalmics AG (Filed With SEC on March 10, 2022)

Basic Sale and Purchase Agreement, dated as of August 18, 2021, by and between the Company and Wakamoto Pharmaceutical Co., Ltd (Filed With SEC on November 9, 2021)

Loan and Security Agreement, dated September 1, 2021, by and between the Company and Melt Pharmaceuticals, Inc (Filed With SEC on September 2, 2021)

Underwriting Agreement, dated as of June 14, 2021, by and among the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein (Filed With SEC on June 17, 2021)

Securities Purchase Agreement, dated as of May 5, 2021, by and between the Company and B. Riley Securities, Inc (Filed With SEC on May 5, 2021)

Underwriting Agreement, dated as of April 15, 2021, by and between the Company and B. Riley Securities, Inc., as representative of the several underwriters named therein (Filed With SEC on April 20, 2021)

Indenture, dated as of April 20, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on April 20, 2021)

First Supplemental Indenture, dated as of April 20, 2021, by and between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on April 20, 2021)

Underwriting Agreement, dated as of April 8, 2021, by and among Harrow Health, Inc., Eton Pharmaceuticals, Inc. and National Securities Corporation (Filed With SEC on April 8, 2021)

Business Loan Agreement with Renasant Bank pursuant to the Paycheck Protection Program, dated April 27, 2020 (Filed With SEC on August 10, 2020)

Asset Purchase Agreement, dated July 26, 2019, by and between Park Compounding, Inc. and Noice Rx, LLC (Filed With SEC on November 13, 2019)

Loan Agreement, dated July 26, 2019, by and between Park Compounding, Inc. and Noice Rx, LLC (Filed With SEC on November 13, 2019)

Joinder and Amendment to Loan and Security Agreement, dated May 24, 2019, by and between Harrow Health, Inc., each of its wholly-owned subsidiaries and SWK Funding LLC (Filed With SEC on May 29, 2019)

Asset Purchase Agreement dated February 1, 2019 between Harrow Health, Inc. and Mayfield Pharmaceuticals, Inc (Filed With SEC on May 9, 2019)

Asset Purchase Agreement dated February 1, 2019 between Harrow Health, Inc. and Elle Pharmaceuticals, Inc (Filed With SEC on May 9, 2019)

Asset Purchase Agreement dated December 11, 2018 between Imprimis Pharmaceuticals, Inc. and Melt Pharmaceuticals, Inc (Filed With SEC on February 5, 2019)

Asset Purchase and License Agreement dated September 28, 2017 between Imprimis Pharmaceuticals, Inc. and Surface Pharmaceuticals, Inc (Filed With SEC on May 15, 2018)

Amend and Restated Asset Purchase and License Agreement dated April 10, 2018 between Imprimis Pharmaceuticals, Inc. and Surface Pharmaceuticals, Inc (Filed With SEC on May 15, 2018)

LOANAND SECURITY AGREEMENT (Filed With SEC on July 20, 2017)

IMPRIMISPHARMACEUTICALS, INC. 2017INCENTIVE STOCK AND AWARDS PLAN INCENTIVESTOCK OPTION AGREEMENT (Filed With SEC on June 16, 2017)

IMPRIMISPHARMACEUTICALS, INC. 2017INCENTIVE STOCK AND AWARD PLAN FORMOF NONQUALIFIEDSTOCK OPTION AGREEMENT (Filed With SEC on June 16, 2017)

IMPRIMISPHARMACEUTICALS, INC. 2017INCENTIVE STOCK AND AWARDS PLAN NOTICEOF RESTRICTED STOCK AWARD (Filed With SEC on June 16, 2017)

IMPRIMISPHARMACEUTICALS, INC. 2017INCENTIVE STOCK AND AWARDS PLAN NOTICEOF Restricted Stock Unit AWARD (Filed With SEC on June 16, 2017)

THIRDAMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on December 29, 2016)

EXCHANGEAND DISCHARGE AGREEMENT (Filed With SEC on December 29, 2016)

AMENDMENTNO. 2 TO WARRANT TO PURCHASE STOCK (Filed With SEC on December 29, 2016)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on December 23, 2016)

IMPRIMISPHARMACEUTICALS, INC. COMMONSTOCK PURCHASE WARRANT (Filed With SEC on December 23, 2016)

IMPRIMISPHARMACEUTICALS, inc. 2,900,000 SHARESOF COMMON STOCK UNDERWRITINGAGREEMENT (Filed With SEC on March 11, 2016)

IMPRIMISPHARMACEUTICALS, INC. 8.00%Convertible Senior Secured Note (Filed With SEC on January 25, 2016)

Imprimis Pharmaceuticals, Inc. 8.00% Convertible Senior Secured Note Note Purchase Agreement (Filed With SEC on January 25, 2016)